Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-672 in Japanese Subjects with Acquired Hemophilia A
NCT04580407Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant coagulation factor viii in acquired hemophilia A (AHA), sponsored by Takeda. Started Apr 2021; status: completed.
02
Drugs
recombinant coagulation factor viii
03
Conditions
acquired hemophilia A (AHA)
Beyond the preview
Go deeper on NCT04580407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580407.